borderline significantP = 0.052
The results of stratification for the overall stage revealed a borderline significant difference in LRRFS, favouring treatment with IMRT in patients with stage III–IV disease (HR: 0.29; 95% CI: 0.08–1.10; P = 0.052).
The results of stratification for the overall stage revealed a borderline significant difference in LRRFS, favouring treatment with IMRT in patients with stage III–IV disease (HR: 0.29; 95% CI: 0.08–1.10; P = 0.052).